glp-1 patent expiration Ozempic, Wegovy and Rybelsus: The patents behind Novo Nordisk's weight-loss drugs 8 key drug patents expiring

Avoid microbiome disruptors Certain dietary and lifestyle factors actively harm the bacteria you are trying to establish: Artificial sweeteners (sucralose and saccharin have been shown to negatively affect gut bacteria composition) Excessive alcohol (disrupts gut barrier integrity and kills beneficial bacteria) Highly processed foods (low in fiber, high in additives that harm microbial diversity) Unnecessary antibiotics (the single biggest destroyer of probiotic colonization) Chronic stress (documented effects on gut microbiome composition through the gut-brain axis) People who are working to optimize their metabolic health, whether through dietary modifications alongside GLP-1 medications or through natural approaches, should prioritize removing these disruptors alongside adding beneficial interventions

In contrast, small increases in activity (roughly up to ~30 minutes above baseline) show little change in recovery metrics

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

Discuss potential side effects and management strategies openly

2.1 SV Labs Corporation Date of Issuance: December 09, 2025 Location: United States Product Type: Finished Pharmaceuticals (OTC) SV Labs Corporation was subject to a significant enforcement action following an inspection that revealed systemic failures in the oversight of automated systems used for both laboratory testing and critical utility monitoring